scholarly journals Performance Dynamics of Splice Ar Variants Redefine Constitutive Reactivation of the Androgen Receptor in Recurrent Prostatic Cancer Patients

2017 ◽  
Vol 6 (4) ◽  
Author(s):  
Lawrence M Agius
Keyword(s):  
Androgen Receptor ◽  
Cancer Patients ◽  
Prostatic Cancer

scholarly journals Effect of oestrogen on liver function of prostatic cancer patients

BMJ ◽  
1969 ◽  
Vol 4 (5677) ◽  
pp. 204-205 ◽  
Author(s):  
M. Kontturi ◽  
E. Sotaniemi
Keyword(s):  
Liver Function ◽  
Cancer Patients ◽  
Prostatic Cancer

scholarly journals Medical ovariectomy in menopausal breast cancer patients with high testosterone levels: a further step toward tailored therapy

2017 ◽  
Vol 24 (11) ◽  
pp. C21-C29 ◽  
Author(s):  
Giorgio Secreto ◽  
Paola Muti ◽  
Milena Sant ◽  
Elisabetta Meneghini ◽  
Vittorio Krogh
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Androgen Receptor ◽  
Growth Factor ◽  
Cancer Patients ◽  
Serum Testosterone ◽  
Late Relapse ◽  
Breast Cancer Patients ◽  
Estrogen Receptor Positive ◽  
Epidermal Growth

Five years of adjuvant therapy with anti-estrogens reduce the incidence of disease progression by about 50% in estrogen receptor-positive breast cancer patients, but late relapse can still occur after anti-estrogens have been discontinued. In these patients, excessive androgen production may account for renewed excessive estrogen formation and increased risks of late relapse. In the 50% of patients who do not benefit with anti-estrogens, the effect of therapy is limited by de novo or acquired resistance to treatment. Androgen receptor and epidermal growth factor receptor overexpression are recognized mechanisms of endocrine resistance suggesting the involvement of androgens as activators of the androgen receptor pathway and as stimulators of epidermal growth factor synthesis and function. Data from a series of prospective studies on operable breast cancer patients, showing high serum testosterone levels are associated to increased risk of recurrence, provide further support to a role for androgens in breast cancer progression. According to the above reported evidence, we proposed to counteract excessive androgen production in the adjuvant setting of estrogen receptor-positive patients and suggested selecting postmenopausal patients with elevated levels of serum testosterone, marker of ovarian hyperandrogenemia, for adjuvant treatment with a gonadotropins-releasing hormone analogue (medical oophorectomy) in addition to standard therapy with anti-estrogens. The proposed approach provides an attempt of personalized medicine that needs to be further investigated in clinical trials.

scholarly journals Clinical profile, BRCA2 expression, and the androgen receptor CAG repeat region in Egyptian and Moroccan male breast cancer patients

2011 ◽  
Vol 33 (1) ◽  
pp. 17-26 ◽  
Author(s):  
Samuel F. Gilbert ◽  
Amr S. Soliman ◽  
Mehdi Karkouri ◽  
Meaghen Quinlan-Davidson ◽  
Ashley Strahley ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Cancer Patients ◽  
Male Breast Cancer ◽  
Male Breast ◽  
Cag Repeat ◽  
Clinical Profile ◽  
Breast Cancer Patients ◽  
Repeat Region

scholarly journals Misceláneos

2018 ◽  
Vol 5 (2) ◽  
pp. 90-93
Author(s):  
Asociación Colombiana de Endocrinología Diabetes y Metabolismo
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Androgen Receptor ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Cartagena De Indias

Listado Póster El Estado República de Colombia cuenta con precedente constitucional jurisprudencial T-622 de 2014, sentencia que reafirma la importancia del diagnóstico certero de los pacientes INTERSEXUALES y actualiza cómo mira el Estado a estos pacientes.  S. Chahin, F. Mejía Póster Caso emblemático “XXXX” estado intersexual demanda efectiva prevalencia “regla jurisprudencial constitucional pro infancia” por ausencia de asertivo reconocimiento gonadal civil, “REGOCI”. S. Chahin, F. Mejia. Póster Utilidad de la plasmaféresis en pancreatitis aguda por hipertrigliceridemia: a propósito de un caso.  Concha Mejía Alejandro, Montaño Padilla Gina Sofía, Rincón Reinaldo, Rodríguez Ruiz Karen Póster Correlation between androgen receptor / estrogen receptor ratio and A 5-Genes proliferation signature in estrogen receptorpositive breast cancer patients.  Rangel N, Rondon-Lagos M, Annaratone L, Cassoni P, Sapino A, Castellano I. Póster Hipogonadismo obesogénico y respuesta a la terapia de remplazo hormonal: presentación de una serie de casos.  Palacio JI, Jaramillo A, Rosero RJ. Póster Terapia con lutecio en pacientes con tumores neuroendocrinos bien diferenciados en progresión. Clínica las américas 2012-2018, Medellín, Colombia. Reporte de casos.  Vásquez M., Aristizábal N., Torres JL., Quintero FM. Póster Cirugía mínimamente invasiva video-asistida para corazón carcinoide.  Velásquez-Uribe OA, Muñoz E, Morales S, Gandara J, Román-González A . Póster Histopatología testicular de ratas BIOU: Wistar expuestas a malatión.  Serrano RA, Hernández GA, Hung S, Lozano R, Paoli M, Gómez Pérez R. Póster Posible efecto de la altitud en la aparición de paragangliomas.  Oscar Arcos, Viviana Fuentes, María Fernanda Zambrano, Jackeline Munier, Alex Valenzuela, Miguel Omehara, Fernando Lizcano. Póster Infecciones asociadas a la atención en salud en pacientes endocrinológicos en unidades de cuidados intensivos, Cartagena de Indias, Colombia. Ochoa Díaz MM, Gómez Camargo D.

scholarly journals Prognostic Role of Androgen Receptor Expression in Surgically Resected Early Breast Cancer Patients

2020 ◽  
Vol 23 (2) ◽  
pp. 182 ◽  
Author(s):  
Yaewon Yang ◽  
Ahrum Min ◽  
Kyung-Hun Lee ◽  
Han Suk Ryu ◽  
Tae-Yong Kim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Receptor Expression ◽  
Androgen Receptor Expression ◽  
Breast Cancer Patients ◽  
Prognostic Role

PSA and radicai prostatectomy

1995 ◽  
Vol 62 (3) ◽  
pp. 422-424
Author(s):  
F. Zattoni
Keyword(s):  
Cancer Patients ◽  
Metastatic Disease ◽  
Adjuvant Treatment ◽  
Prostatic Cancer ◽  
Prostatic Tissue ◽  
Reliable Marker

PSA represents a very reliable marker in the evaluation of prostatic cancer patients. Particularly in those who have undergone radicai prostatectomy, finding dosable values of serum PSA, that theoretically shouldn't occur, must be regarded as the persistence, at least, of residuai prostatic tissue. An increase of such concentrations raises doubts of locai recurrence or metastatic disease. Every effort must be made to demonstrate this event as soon as possible in order to apply an adjuvant treatment. Non-disappearance of serum PSA at 3 months after surgery has to be inevitably considered as a lack of surgical radicality.

YB-1 variant and androgen receptor axis-targeted agents in metastatic castration-resistant prostate cancer patients

2020 ◽  
Vol 21 (13) ◽  
pp. 919-928
Author(s):  
Ana Afonso ◽  
Jani Silva ◽  
Ana Rita Lopes ◽  
Sara Coelho ◽  
Ana Sofia Patrão ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Cancer Patients ◽  
Cox Regression ◽  
Progression Free Survival ◽  
Castration Resistant Prostate Cancer ◽  
Allelic Discrimination ◽  
Cox Regression Analysis ◽  
Castration Resistant ◽  
Increased Risk

Aim: To evaluate the influence of YB-1 rs10493112 variant as a genetic marker for response to second-generation androgen receptor axis-target agents. Methods: A hospital-based cohort study of 78 patients with metastatic castration-resistant prostate cancer was conducted. Genotyping was performed by TaqMan® allelic discrimination technology. Main results: In abiraterone-treated and high-risk patients, YB-1 rs10493112 AA genotype carriers showed lower progression-free survival than C allele genotype patients (4 vs 17 months; p = 0.009). For carriers of AA genotype, multivariate Cox regression analysis revealed a fivefold increased risk of progression (p = 0.035). Conclusion: The study findings suggest that, for metastatic and castration-resistant prostate cancer patients, this polymorphism might be a putative marker for the clinical outcome.

Sign in / Sign up

Export Citation Format

Share Document